Halozyme Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · San Diego, CA
HALO chart
What traders are saying about $HALO
Latest postsHalozyme Therapeutics, Inc. news
- Halozyme Therapeutics (HALO) Could Be 16% Below Fair Value After Royalty Fueled Growth
Simply Wall Street ·
- Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth Momentum
Yahoo Finance ·
- Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history
Yahoo Finance Singapore ·
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Yahoo Finance ·
- Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Yahoo Finance ·
- RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
Yahoo Finance ·
- How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs
Yahoo Finance ·
- BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.
Yahoo Finance ·
- Halozyme Therapeutics stock hits all-time high at 125.53 USD
Investing.com ·
- MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
Yahoo Finance ·
- Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Yahoo Finance ·
- Halozyme Therapeutics, Inc. Estimates – NASDAQ:HALO
TradingView ·
Halozyme Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M |
| Diluted EPS | $2.56 | $3.43 | $2.10 | $1.44 |
| Total assets (year end) | $2.53B | $2.06B | $1.73B | $1.84B |
| Cash and equivalents (year end) | $133.8M | $115.8M | $118.4M | $234.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Halozyme Therapeutics, Inc.
- Ticker
- HALO (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1159036
- Former names
- HALOZYME THERAPEUTICS INC, GLOBAL YACHT SERVICES INC
Frequently asked questions
What exchange is Halozyme Therapeutics, Inc. listed on?
Halozyme Therapeutics, Inc. trades on the Nasdaq under the ticker symbol HALO.
What industry is Halozyme Therapeutics, Inc. in?
Halozyme Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Halozyme Therapeutics, Inc. headquartered?
Halozyme Therapeutics, Inc.'s business address on file with the SEC is in San Diego, CA.
When does Halozyme Therapeutics, Inc.'s fiscal year end?
Halozyme Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Halozyme Therapeutics, Inc. report?
Halozyme Therapeutics, Inc. reported $1.40B in revenue for calendar year 2025, according to its SEC filings.